About 10% of patients with LEMS have concomitant PCD [20,21], associated with the reduction of the P/Q type VGCCs in the molecular layer of the cerebellum [21] at neuropathology, suggestive of a pathogenic role of the P/Q type VGCC antibodies. This evidence concerns the gene OCA2 and Lambert-Eaton myasthenic syndrome.